Factor V Leiden: Definition, Evaluation, and Management
Factor V Leiden (FVL) is a genetic mutation (Arg506Gln) causing resistance to activated protein C, making it the most common inherited thrombophilia in people of European descent 1, 2.
What is Factor V Leiden?
Factor V Leiden is a single point mutation that impairs the anticoagulant response to activated protein C, resulting in a hypercoagulable state with increased venous thromboembolism (VTE) risk. The mutation prevents normal inactivation of factor V, leading to excessive thrombin generation 3.
Risk Stratification by Genotype
- Heterozygotes: ~10% lifetime VTE risk 4
- Homozygotes: >80% lifetime VTE risk 4
- Double heterozygotes (FVL + prothrombin 20210A): High recurrence risk, managed similarly to homozygotes 4
Importantly, recent data suggests that aside from higher VTE prevalence and modestly reduced VTE-free survival, the clinical phenotype severity does not differ dramatically between heterozygotes and homozygotes 5. However, homozygotes still warrant more aggressive management.
When to Test for Factor V Leiden
Recommended Testing Scenarios 1, 4:
Test in these high-yield situations:
- Age <50 with any VTE
- VTE at unusual sites (cerebral, hepatic, mesenteric, splanchnic veins)
- Recurrent VTE
- VTE provoked by pregnancy or postpartum
- VTE associated with oral contraceptive use
- VTE with positive family history (first- or second-degree relative with thrombophilia OR first-degree relative with VTE at young age)
- Low APC resistance on functional testing
- Siblings of known FVL homozygotes
Consider Testing In:
- VTE age >50 (unless active malignancy present) 4
- Asymptomatic relatives of known FVL carriers (particularly women contemplating pregnancy or oral contraceptives) 1, 4
- Women with recurrent late-trimester pregnancy loss, severe preeclampsia, placental abruption, intrauterine growth retardation, or stillbirth 4
- Young female smokers (<45-50 years) with myocardial infarction 4
Do NOT Test:
- General population screening 4
- Routine screening before oral contraceptive use in asymptomatic women without personal/family history 4
- Arterial thrombosis (except young female smokers with MI) 4
- Routine prenatal or newborn screening 4
- Patients with active malignancy and VTE 4
Critical caveat: The 2025 ACMG guidelines 1 emphasize that testing should only be performed when results will influence treatment decisions and clinical management, not for academic interest alone.
Diagnostic Testing Approach
Use DNA-based genotyping as the primary test, especially for family members of known carriers 1, 4. DNA testing definitively distinguishes heterozygotes from homozygotes, which is crucial for management decisions.
Alternative approach: Functional APC resistance assay followed by DNA confirmation if positive 4. However, proceed directly to DNA testing if:
- Patient on heparin
- Known lupus anticoagulant present
- Testing relatives of confirmed carriers
Important: Direct oral anticoagulants (dabigatran, rivaroxaban, argatroban, bivalirudin) can cause discrepant APC resistance results 3. DNA testing avoids this interference.
Management of Heterozygous Carriers
Acute VTE Treatment
Treat the first acute VTE according to standard anticoagulation guidelines regardless of FVL status 2. The presence of heterozygous FVL does not change initial management.
Duration of Anticoagulation After First VTE
For heterozygous FVL carriers, anticoagulation duration decisions should be based on whether the VTE was provoked or unprovoked, NOT solely on FVL status 4, 2. Current evidence suggests FVL heterozygosity has at most a modest effect on recurrence risk 2.
- Provoked VTE: Standard duration (3-6 months) is typically sufficient
- Unprovoked VTE: Consider extended anticoagulation based on bleeding risk assessment, not FVL status alone
- Recurrent VTE: Many clinicians recommend indefinite anticoagulation regardless of genetic status 4
Critical distinction: Heterozygous FVL alone does NOT mandate lifelong anticoagulation after a single provoked VTE 2.
Asymptomatic Heterozygous Carriers
Long-term anticoagulation is NOT routinely recommended for asymptomatic heterozygous FVL carriers 2. Instead, focus on:
Situational Prophylaxis:
- Surgery/hospitalization: Standard VTE prophylaxis (all patients should receive this regardless of FVL status) 4
- Pregnancy/postpartum: Consider prophylactic anticoagulation, particularly postpartum when risk is highest 1, 6
- Extended travel: Counsel on mobility, hydration, possible compression stockings
- Immobilization: Prophylactic anticoagulation during prolonged immobility
Oral Contraceptives:
Do NOT routinely screen asymptomatic women before prescribing oral contraceptives 4. The absolute risk remains low despite a 30-fold relative risk increase. Screening 2 million women would prevent only one death while denying contraception to 90,000 carriers, leading to increased pregnancy complications 4.
However, test women with:
- Personal history of VTE
- First-degree relative with VTE history
- Known family history of FVL or thrombophilia
If heterozygous FVL is identified: Counsel about risks and offer alternative contraception, but the decision should be individualized based on the woman's preferences and other risk factors 4.
Management of Homozygous Carriers
Homozygous FVL carriers require more aggressive management 4:
- After any VTE: Strongly consider lifelong anticoagulation (though weigh against 8% annual major bleeding risk with warfarin) 4
- Asymptomatic homozygotes: Do not require routine anticoagulation, but aggressive prophylaxis during high-risk periods is essential 1
- Pregnancy: Prophylactic anticoagulation should be strongly considered throughout pregnancy and postpartum 1, 6
Additional Testing Considerations
Test for prothrombin 20210A mutation in all FVL-positive patients 4. Double heterozygotes have significantly elevated recurrence risk and should be managed similarly to homozygotes 4.
Do NOT test for MTHFR variants 1. Recent meta-analyses show no significant association with VTE, and ACMG explicitly recommends against routine MTHFR testing for thrombophilia.
Key Clinical Pitfalls
Don't over-anticoagulate heterozygotes: The lifetime VTE risk is only ~10%, and most will never have an event 4
Don't screen everyone: Testing should be targeted to situations where results change management 1
Don't withhold oral contraceptives based on family history alone: Test first if there's a concerning family history, but don't deny contraception without confirmed carrier status 4
Don't forget about homozygotes: These patients (1.5% of VTE patients <70 years) need identification because their management differs substantially 4
Remember age is not a barrier: First VTE in FVL carriers often occurs after age 50, so don't exclude older patients from testing based on age alone 4
Pregnancy complications: While FVL is associated with pregnancy loss and complications, the probability of successful pregnancy remains high even in carriers 2